CEVA-101

N/A

Report date: 2022/12/02 17:14:49

Base Information

Drug NameCEVA-101
Drug Alias Nameautologous bone marrow mononuclear cell therapyAutologous bone marrow-derived stem cellsAutologous bone marrow mononuclear cellsAutologous BMMNCsCEVA-001 +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy > Monocyte cell therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsBrain Injuries
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUT Health San AntonioNational Institute Of Neurological Disorders And Stroke
China Registration ClassN/A

Develop Information

Active CompaniesFortress Biotech IncUT Health San AntonioNational Institute Of Neurological Disorders And Stroke
Inactive CompaniesN/A
Active IndicationsBrain Injuries
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A